TNXP
Income statement / Annual
Last year (2023), Tonix Pharmaceuticals Holding Corp.'s total revenue was $7.77 M,
and the percentage change from the previous year is not available.
In 2023, Tonix Pharmaceuticals Holding Corp.'s net income was -$116.66 M.
See Tonix Pharmaceuticals Holding Corp.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$7.77 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$4.74 M |
$112.09 M |
$92.31 M |
$50.51 M |
$28.83 M |
$26.32 M |
$21.29 M |
$38.97 M |
$48.16 M |
$27.66 M |
| Gross Profit |
$3.03 M |
-$112.09 M |
-$92.31 M |
-$50.51 M |
-$28.83 M |
-$26.32 M |
-$21.29 M |
-$38.97 M |
-$48.16 M |
-$27.66 M |
| Gross Profit Ratio |
0.39 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$86.66 M
|
$81.88 M
|
$68.84 M
|
$36.16 M
|
$18.19 M
|
$17.56 M
|
$13.34 M
|
$28.53 M
|
$35.50 M
|
$18.62 M
|
| General & Administrative
Expenses |
$34.75 M
|
$30.22 M
|
$23.47 M
|
$14.35 M
|
$10.64 M
|
$8.76 M
|
$7.95 M
|
$10.44 M
|
$12.66 M
|
$9.04 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$34.75 M
|
$30.22 M
|
$23.47 M
|
$14.35 M
|
$10.64 M
|
$8.76 M
|
$7.95 M
|
$10.44 M
|
$12.66 M
|
$9.04 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$121.41 M |
$112.09 M |
$92.31 M |
$50.51 M |
$28.83 M |
$26.32 M |
$21.29 M |
$38.97 M |
$48.16 M |
$27.66 M |
| Cost And Expenses |
$126.15 M |
$112.09 M |
$92.31 M |
$50.51 M |
$28.83 M |
$26.32 M |
$21.29 M |
$38.97 M |
$48.16 M |
$27.66 M |
| Interest Income |
$0.00 |
$1.87 M |
$25,000.00 |
$48,000.00 |
$210,000.00 |
$233,000.00 |
$168,000.00 |
$127,000.00 |
$108,000.00 |
$40,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$4.29 M
|
$1.25 M
|
$50,000.00
|
$27,000.00
|
$26,000.00
|
$54,000.00
|
$64,000.00
|
$206,000.00
|
$161,000.00
|
$36,000.00
|
| EBITDA |
-$114.09 M
|
-$110.84 M
|
-$92.26 M
|
-$50.48 M
|
-$28.80 M
|
-$26.27 M
|
-$21.06 M
|
-$38.76 M
|
-$48.00 M
|
-$27.62 M
|
| EBITDA Ratio |
-14.69 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-15.24
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$1.72 M
|
$1.87 M
|
$25,000.00
|
$48,000.00
|
$210,000.00
|
$233,000.00
|
$168,000.00
|
$127,000.00
|
$108,000.00
|
$40,000.00
|
| Income Before Tax |
-$116.66 M |
-$110.22 M |
-$92.29 M |
-$50.46 M |
-$28.62 M |
-$26.09 M |
-$21.12 M |
-$38.84 M |
-$48.05 M |
-$27.62 M |
| Income Before Tax Ratio
|
-15.02
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$4.79 M |
-$75,000.00 |
-$75,000.00 |
-$236,000.00 |
$233,000.00 |
-$70,000.00 |
-$206,000.00 |
-$161,000.00 |
-$36,000.00 |
| Net Income |
-$116.66 M |
-$116.88 M |
-$92.29 M |
-$52.17 M |
-$31.09 M |
-$29.36 M |
-$21.12 M |
-$38.84 M |
-$48.05 M |
-$27.62 M |
| Net Income Ratio |
-15.02 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-219.09 |
-640.26 |
-1620.86 |
-3530.04 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS Diluted |
-219.09 |
-640.26 |
-1620.86 |
-3530.04 |
0 |
0 |
0 |
0 |
0 |
0 |
| Weighted Average Shares
Out |
$532,478.00
|
$182,545.00
|
$56,937.00
|
$14,780.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$532,478.00
|
$182,545.00
|
$56,937.00
|
$14,780.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
